Comparative Pharmacology
Head-to-head clinical analysis: VALACYCLOVIR HYDROCHLORIDE versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALACYCLOVIR HYDROCHLORIDE versus VITRAVENE PRESERVATIVE FREE.
VALACYCLOVIR HYDROCHLORIDE vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valacyclovir hydrochloride is a prodrug of acyclovir. After oral administration, it is rapidly converted to acyclovir, which inhibits viral DNA polymerase, leading to chain termination and inhibition of viral DNA replication.
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
500 mg orally twice daily for recurrent genital herpes; 1 g orally twice daily for herpes zoster; 1 g orally three times daily for herpes simplex encephalitis or immunocompromised patients.
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.3 hours in patients with normal renal function; prolonged to 14 hours in renal impairment (CrCl 15–30 mL/min).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Renal excretion: >90% as unchanged drug and inactive metabolite (9-carboxymethoxymethylguanine). Biliary/fecal: <2%.
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category A/B
Category C
Antiviral
Antiviral